The Critical Limb Ischemia Treatment market involves products utilized for management of persistent and progressive ischemia of tissues and organs. Treatment options include endovascular and surgical procedures. Angioplasty, stenting, and atherectomy devices are commonly used for revascularization to improve blood flow. Advancements in balloon and drug eluting technologies have widened treatment scope for critical limb ischemia.
The Global Critical Limb Ischemia Treatment Market is estimated to be valued at US$ 9.11 Bn in 2024 and is expected to exhibit a CAGR of 8.5% over the forecast period from 2024 to 2031.
Key Takeaways
Companies operating in the Critical Limb Ischemia Treatment Market Share are Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Cook Medical Inc., Cardiovascular Systems, Inc., Philips Healthcare, B. Braun Melsungen AG, Terumo Corporation, Biotronik SE & Co. KG, Cordis Corporation, Smith & Nephew plc, Stryker Corporation, AngioDynamics, Inc., GE Healthcare, Sanofi S.A., AstraZeneca plc, and Bristol-Myers Squibb Company. The growing geriatric population and rising prevalence of peripheral artery diseases globally is fueling demand in the critical limb ischemia treatment market. Moreover, increasing healthcare expenditure and research funding for treatment of cardiovascular disorders is supporting the expansion of critical limb ischemia treatment market across major markets.
Market key trends
The rising preference for minimally invasive procedures over conventional open surgeries is a major trend in the Critical Limb Ischemia Treatment Market Demand. Endovascular procedures such as balloon angioplasty allow restoration of blood flow with minimal incision and reduced post-operative recovery time. Development of advanced catheters and guidewires suitable for complex revascularization procedures is also supporting growth of endovascular modalities for CLI management.
Porter’s Analysis
Threat of new entrants: Low economies of scale and high capital requirements prevent new entrants, especially in surgical equipment.
Bargaining power of buyers: Buyers have low bargaining power due to lack of viable substitutes and importance of treatments to patients’ health.
Bargaining power of suppliers: Suppliers of drugs and devices have moderate power due to differentiation and regulations.
Threat of new substitutes: No major substitutes exist for treating advanced peripheral artery disease, giving existing treatments protection from substitutes.
Competitive rivalry: Intense competition exists among surgical and pharmaceutical companies due to importance of treatments and barriers to differentiation.
Geographical Regions
North America currently holds the largest share of the global critical limb ischemia treatment market in terms of value, owing to growing prevalence of peripheral artery disease, high healthcare spending, and technically advanced healthcare facilities. The United States alone accounts for over 80% of the North American market, making it the most lucrative country globally.
Asia Pacific is poised to be the fastest growing region for the critical limb ischemia treatment market during the forecast period. This is attributed to increasing healthcare expenditure, growing geriatric population, rising incidence of diabetes and its complications, and improving access to healthcare in Asia Pacific countries. China and India are expected to lead market growth due to their large population bases and growing patient pool.